BioScience Health Innovations, Inc.
BioScience Health Innovations, Inc.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets Current | |||||||||||||||||
Assets Current | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Inventory Net | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | |||||
Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | - | |||||
Deferred Income Tax Assets Net | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Other Assets | |||||||||||||||||
Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | |||||
Liabilities And Stockhold… | |||||||||||||||||
Deposits Assets Noncurrent | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Operating Lease Right Of Use Asset | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Assets Noncurrent | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Assets | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Taxes Payable Current | 0 | 0 | - | - | - | 0 | - | - | - | - | - | - | |||||
Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | |||||
Notes Payable Current | 0 | - | - | - | - | - | - | - | - | - | - | - | |||||
Liabilities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Stockholders Equity Defic… | |||||||||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |||||
Stockholders Equity | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | -0 | 0 | -0 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | 0 | 0 | 1 | 1 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |||||
Liabilities And Stockholders Equity | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | - | - | - | - | - | 0 | - | - | - | 0 | - | - | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Issued | 46 | 44 | 44 | 44 | 44 | 44 | 42 | 42 | 42 | 41 | 41 | 40 | |||||
Shares Outstanding | 44 | 44 | 44 | 44 | 44 | 44 | 42 | 42 | 42 | 41 | 41 | 40 | |||||
Common Stock Shares Authorized | 250 | 250 | 250 | 225 | 225 | 250 | 225 | 225 | 225 | 225 | 225 | 225 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.37% | 4.10% | - | - | - | - | - | - | - | - | - | - |
| 2025 | 0.00% | 0.00% | -92.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 207.69% | 95.19% | 98.44% |
| 2024 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | - | - | - |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 2.80 | 4.41 | 3.81 | 3.67 | 3.61 | 3.82 | 6.02 | 8.37 | 9.25 | 11.70 | 4.77 | 2.57 | |||||
| Days Sales Outstanding TTM | 6.01 | 16.03 | 3.67 | 18.29 | 7.50 | 13.53 | 6.01 | 6.85 | 5.47 | 22.26 | 23.24 | 56.72 | |||||
| Receivables Turnover TTM | 60.71 | 22.78 | 99.37 | 19.96 | 48.65 | 26.99 | 60.77 | 53.28 | 66.68 | 16.40 | 15.71 | 6.44 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.00 | 0.06 | 0.08 | 0.09 | 0.05 | 0.01 | 0.00 | -0.01 | -0.02 | -0.03 | -0.02 | - | |||||
| Free Cash Flow Per Share TTM | -0.06 | 0.01 | 0.01 | 0.05 | 0.03 | -0.00 | 0.01 | -0.01 | -0.03 | -0.04 | -0.04 | -0.00 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 54.29% | 56.97% | 63.64% | 65.61% | 70.51% | 70.94% | 78.42% | 81.38% | 82.05% | 81.06% | - | - | |||||
| Operating Profit Margin TTM | 1.20% | 12.64% | 18.74% | 22.81% | 20.30% | 4.72% | 2.51% | -6.45% | -27.78% | -42.09% | -79.31% | -201.28% | |||||
| Net Profit Margin TTM | -0.28% | 11.29% | 18.74% | 22.81% | 20.30% | 4.72% | 2.51% | -6.45% | -27.78% | -42.09% | -79.30% | -201.25% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 86.53% | 208.34% | 207.22% | 260.04% | 231.54% | 208.73% | 423.31% | 1,037.07% | 3,370.27% | - | - | - | |||||
| Net Income Growth (1Y) | -102.58% | 638.03% | 2,190.52% | -1,372.96% | -342.21% | -134.59% | -116.59% | -63.55% | 51.56% | 193.58% | 180.15% | 199.62% | |||||
| EPS Growth (1Y) | -102.49% | 604.72% | 2,085.17% | -1,305.71% | -328.29% | -127.85% | -115.98% | 41.30% | 39.98% | 232.41% | 961.41% | 184.14% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -1,642.49 | 68.40 | 49.58 | 600.54 | 1,006.58 | 6,266.00 | 14,085.68 | -7,240.81 | -2,297.93 | -1,745.29 | -2,250.95 | -10,231.62 | |||||
| P/B TTM | 14.25 | 29.73 | 25.67 | 331.97 | 452.37 | 652.68 | 1,470.90 | 2,859.89 | 4,684.82 | -64,932.07 | 60,999.30 | -38,639.22 | |||||
| P/S TTM | 4.61 | 7.72 | 9.29 | 136.98 | 204.30 | 295.48 | 354.04 | 467.15 | 638.41 | 734.51 | 1,784.95 | 20,591.49 | |||||
| Market Cap | 24.01M | 43.92M | 43.92M | 570.91M | 570.91M | 545.14M | 544.65M | 540.75M | 538.09M | 438.94M | 524.72M | 2.10B | |||||
| Enterprise Value | 23.32M | 43.25M | 42.78M | 569.61M | 569.88M | 545.05M | 544.32M | 540.61M | 538.00M | 438.92M | 524.67M | 2.10B | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -735.09K | 115.33K | 157.51K | 543.15K | 343.50K | -2.85K | 143.55K | -105.58K | -289.21K | -307.84K | -365.72K | -189.70K | |||||
| Net Debt | -684.60K | -661.93K | -1.14M | -1.30M | -1.03M | -92.44K | -333.22K | -143.92K | -92.94K | -19.24K | -41.99K | -30.32K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
BioScience Health Innovations, Inc. (BHIC) — SEC Financial Statements & Analysis
BioScience Health Innovations, Inc. (BHIC) is a services-computer processing & data preparation company, incorporated in NV. BioScience Health Innovations, Inc. trades on OTC as: BHIC. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BioScience Health Innovations, Inc. reported a 86.53% year-over-year revenue growth, a Gross Profit Margin of 54.29% (TTM), a Price-to-Sales (P/S) ratio of 4.61x (TTM), a Price-to-Book (P/B) ratio of 14.25 (TTM), at a market cap of $24.01M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 86.53%
- Gross Profit Margin TTM
- 54.29%
- P/S TTM
- 4.61x
- P/B TTM
- 14.25
- Market Cap
- $24.01M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioScience Health Innovations, Inc. in?
BioScience Health Innovations, Inc. (BHIC) operates in the Services-Computer Processing & Data Preparation industry.
What is BHIC's market cap?
BioScience Health Innovations, Inc. (BHIC) has a market capitalization of $24.01M as of 2026-03-31.
What exchange does BHIC trade on?
BioScience Health Innovations, Inc. (BHIC) trades on the OTC.
Where is BioScience Health Innovations, Inc. incorporated?
BioScience Health Innovations, Inc. is incorporated in NV.